Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in HIV Uninfected Adult TB Patients After Treatment Completion

NCT02465216 is registered in ClinicalTrials.gov with Access to Advanced Health Institute (AAHI) as lead sponsor.

NCT NCT02465216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02465216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in HIV Uninfected Adult TB Patients After Treatment Completion
Lead sponsor
Access to Advanced Health Institute (AAHI)
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2015
Completion date
January 31, 2017
Enrollment
60 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary tuberculosis